Kang et al. conducted an in vitro and in vivo study and reported that midazolam could reduce the progression of hepatocellular carcinoma by inhibiting the NF-κB pathway and influence the immune microenvironment with a decrease in the secretion of TNF-α [124]. Here, TNF is linked to hepatocellular carcinoma.